A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 797-804

  Hori, Yasunobu ^a   Matsukawa, Jun ^a   Takeuchi, Toshiyuki ^a   Nishida, Haruyuki ^a   Kajino, Masahiro ^a   Inatomi, Nobuhiro ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (2 FLUOROPHENYL) 1 (PYRIDIN 3 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE MONOFUMARATE; CIMETIDINE; HISTAMINE; LANSOPRAZOLE; POTASSIUM COMPETITIVE ACID BLOCKER; TAK 438; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTI-ULCER AGENTS; CIMETIDINE; DOGS; GASTRIC ACID; GASTRIC MUCOSA; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE; HISTAMINE AGONISTS; HYDROGEN-ION CONCENTRATION; MALE; POTASSIUM; PROTON PUMP INHIBITORS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TIME FACTORS;

EID: 79956193494     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179556     Document Type: Article

References (37)

1. Andersson K and Carlsson E (2005) Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 108:294-307. (Pubitemid 41693765)
2. Ang TL and Fock KM (2006) Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 21(Suppl 5):S125-S128. (Pubitemid 44730214)
3. Bell NJ, Burget D, Howden CW, Wilkinson J, and Hunt RH (1992) Appropriate acid suppression for management of gastro-esophageal reflux disease. Digestion 51(Suppl 1):59-67.
4. Dammann HG and Burkhardt F (1999) Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 11:1277-1282. (Pubitemid 29531351)
5. De Graef J and Woussen-Colle MC (1986) Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 91:333-337. (Pubitemid 16098359)
6. Fellenius E, Elander B, Wallmark B, Helander HF, and Berglindh T (1982) Inhibition of acid secretion on isolated gastric glands by substituted benzimidazoles. Am J Physiol Gastrointest Liver Physiol 243:G505-G510. (Pubitemid 13166247)
7. Forte JG and Yao X (1996) The membrane-recruitment-and-recycling hypothesis of gastric HCl secretion. Trends Cell Biol 6:45-48. (Pubitemid 26031994)
8. Frazzoni M, De Micheli E, Grisendi A, and Savarino V (2003) Effective intraoesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 17:235-241. (Pubitemid 36174254)
9. +-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochem Biophys Acta 307:169-180.
10. +-ATPase. Biochem Pharmacol 73:198-205.
11. Geibel JP (2005) Role of potassium in acid secretion. World J Gastroenterol 11:5259-5265.
12. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, Huang B, and NSAID-Associated Gastric Ulcer Prevention Study Group (2002) Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 162:169-175. (Pubitemid 34098186)
13. Heidenhain R (1879) Ueber die absonderung der fundusdrüsen des magens. Arch Ges Physiol 19:148-166.
14. Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, and Inatomi N (2010) 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl) -1Hpyrrol- 3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335:231-238.
15. Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inomata Y, Makino M, Tabata K, and Shibakawa N (2007) Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl] methyl}-1Hpyrrolo[ 2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther 323:308-317. (Pubitemid 47443260)
16. Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzén S, and Hasselgren G (2007) A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 5:1385-1391. (Pubitemid 350181597)
17. Katz PO, Hatlebakk JG, and Castell DO (2000) Gastric acidity and acid break-through with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 14:709-714. (Pubitemid 30352736)
18. Katz PO, Scheiman JM, and Barkun AN (2006) Review article: acid-related disease-what are the unmet clinical needs? Aliment Pharmacol Ther 23:9-22.
19. Long JF, Chiu PJ, Derelanko MJ, and Steinberg M (1983) Gastric antisecretory and cytoprotective activities of SCH28080. J Pharmacol Exp Ther 226:114-120. (Pubitemid 13026188)
20. Malfertheiner P, Mossner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, and Fuchs W (2003) Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 18:615-625. (Pubitemid 37186611)
21. Matsukawa J, Hori Y, Nishida H, Kajino M, and Inatomi N (2011) A comparative study on the modes of action between TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in animals and cultured rabbit gastric glands. Biochem Pharmacol 81:1145-1151.
22. +-ATPase. J Biol Chem 265:5030-5036.
23. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 248:799-805.
24. Nagaya H, Satoh H, and Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289-1295. (Pubitemid 20127442)
25. Parsons ME and Keeling DJ (2005) Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 14:411-421.
26. Robinson M (2005) Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 59:709-715.
27. Sachs G, Carlsson E, Lindberg P, and Wallmark B (1988) Gastric H, K-ATPase as therapeutic target. Annu Rev Pharmacol Toxicol 28:269-284.
28. + pump in plasma membranes of hog stomach. J Biol Chem 251:7690-7698.
29. +-ATPase. Annu Rev Pharmacol Toxicol 35: 277-305.
30. +-competitive acid blocker TAK-438. Gastroenterology 138:651-652.
31. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, and Postius S (2007) Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 321:866-874. (Pubitemid 46762698)
32. Tytgat GN (2001) Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 13:S29-S33.
33. Vakil N (2004) Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 19:1041-1049.
34. +-ATPase and acid secretion by SCH28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem 262:2077-2084.
35. Wolfe MM and Sachs G (2000) Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 118:S9-S31.
36. Wurst W and Hartmann M (1996) Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med 69:233-243. (Pubitemid 27209696)
37. Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, et al. (2004) Pharmacokinetic and pharmacodynamic evaluation of novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 44: 73-82.